SHARE
COPY LINK

MONOPOLY

Private pharmacies return to Sweden

The first private pharmacy in Sweden since 1971 opened for business in Stockholm on Sunday following an inauguration by Swedish Health and Social Affairs minister Göran Hägglund.

Private pharmacies return to Sweden

“After hard work for a long time, we are now ready to open the first pharmacy in Sweden which is privately owned since 1971,” Hägglund said as reporters and a small crowd looked on.

The state-owned Apoteket chain of pharmacies was until Sunday the sole provider of prescription medication in Sweden, and was until November 2009 also the only provider of non-prescription drugs such as headache tablets or other over-the-counter products.

Sweden’s parliament in May 2008 voted in favour of the centre-right government’s plans to open up the country’s market for prescription and non-prescription drugs to competition.

In November 2009, the Swedish state sold 465 of its estimated 900 state-owned Apoteket stores to four firms, all of them Swedish companies established for the sole purpose of running the pharmacies.

The pharmacy inaugurated on Sunday, in the Kungsholmen district of Stockholm, was the first of such pharmacies to operate under its own brand name. It is operated by Medstop, which has also taken over a further 61 pharmacies across Sweden.

“We want to increase accessibility and think that can be achieved through competition” in the pharmacy market, Hägglund said Sunday of the new pharmacy system.

As of November 1st, 2009, Swedes wanting to buy non-prescription drugs could do so at selected stores, including some gas stations and grocery shops.

The Swedish government has previously argued that putting an end to the Apoteket monopoly would improve the availability of medicines for customers in the form of more pharmacies and longer opening hours, and create downward pressure on prices as more providers entered the market.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

MEDICINE

Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report

Norwegian hepatitis C patients are waiting longer than they should for medical treatment due in part to a monopoly on its supply, according to a report.

Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report
Photo: SimpleFoto/Depositphotos

Between 15,000 and 20,000 Norwegians live with the chronic condition, which is treated with a 12-week course of medicine.

The cost of a 12-week course of the Epclusa medicine in Norway is 540,000 kroner (57,000 euros), according to the Klassekampen newspaper.

American pharmaceutical company Gilead Sciences owns a monopoly on supply of the medicine in the Scandinavian country, according to the report.

The medicine, which can cure the disease, is not prescribed to patients with the type 2 and 3 forms of hepatitis C – around 60 percent of sufferers in Norway – until their livers show clear signs of damage.

Although it can take many years from contracting the disease until the liver starts to fail, patients not given the treatment sooner are left with uncertain physical consequences as well as the psychological distress of living with the infectious condition, writes Klassekampen.

People with hepatitis C are not automatically entitled to the treatment, but are given it once symptoms are present.

Ronny Bjørnestad, head of NGO Prolar, which works to improve understanding of the illness, told Klassekampen that he had decided to obtain the treatment by going abroad.

“I felt I couldn’t wait any longer. I have a ticking bomb in my liver and am still infectious. I have a teenager in my house and it wouldn’t take any more than him accidentally using my razor blade for an accident to happen,” he told Klassekampen.

Bjørnestad said that he had purchased the same medicine for the equivalent of 7,500 kroner (800 euros) in Bangladesh, and then had it sent on to a friend in Scotland.

It is legal for Bjørnestad to bring the medicine back to Norway provided he begins the course of treatment while in Scotland, writes Klassekampen.

“If it was an illness that [mainly] affected a group with stronger resources then this would never have been accepted,” he told the newspaper.

The disease has relatively high prevalence amongst former and active drug addicts.

Olav Dalgard, consultant at the department of infectious diseases at Akershus University Hospital, told Klassekampen that the price of Hepatitis C medicine in Norway is “amorally” high.

“If we had cheaper medicine, we would recommend treatment of far more people at a much earlier stage. It would reduce the risk of disease spread. But prices must be reduced for that to be possible” Dalgard told Klassekampen.

The newspaper has contacted Gilead Sciences for comment. 

READ ALSO: 'More Norwegians than ever' take medication